Alcoholic Liver Diseases Treatment Market: Regional Insights 2025–2033

According to FutureWise analysis, the alcoholic liver diseases treatment market in 2023 was US$2.08 billion, and is expected to reach over US$3 billion by 2031 at a CAGR of 6%.  The recent surge in Alcoholic Liver Diseases Treatment market growth is largely due to the rising prevalence of alcohol-related liver disorders. This has led to increased awareness about the importance of early diagnosis and treatment. Additionally, innovations in therapeutic drugs are playing a crucial role in this development. As more people focus on managing their liver health and preventing lifestyle-related diseases, we can anticipate even greater momentum for market expansion. The growing incidence of alcohol consumption and its associated liver disorders is driving demand for advanced treatment options. Heightened awareness of the importance of early diagnosis, combined with the introduction of new therapeutic approaches, is expected to drive market growth further. Furthermore, supportive government initiatives and increased healthcare investments are contributing to the global expansion of the alcoholic liver disease treatment sector.

Alcoholic liver disease (ALD) refers to liver damage caused by excessive alcohol consumption. Prolonged alcohol use can lead to inflammation and swelling of the liver. ALD represents a major healthcare issue, posing personal and social challenges and causing significant economic losses worldwide. The spectrum of ALD includes alcoholic fatty liver, cirrhosis, alcoholic hepatitis, and the potential development of hepatocellular carcinoma. Diagnosis of alcoholic liver disease relies on clinical characteristics, which include evidence of liver damage, a history of significant alcohol intake, and results from laboratory tests.

Addressing the underlying alcohol addiction is the most crucial step in managing alcoholic liver disease (ALD). Abstinence from alcohol is the cornerstone of treatment. Nutritional therapy is typically the first-line treatment for this condition. The use of steroids in patients with mild to severe alcoholic hepatitis is becoming more accepted, provided that these patients are assessed for therapy effectiveness after one week. Pentoxifylline is particularly beneficial for ALD patients with renal dysfunction. Biological therapies, such as specific anti-TNF agents, have shown disappointing results and should likely be limited to clinical trial settings. Transplantation has positive outcomes for patients with advanced ALD who have ceased alcohol consumption, demonstrating exceptional long-term graft and patient survival rates.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Alcoholic Liver Diseases Treatment Market trends that shall affect the overall market growth.

Request a Free Sample @

https://www.futurewiseresearch.com/contact.aspx?rpt=11852&type=requestsample

By Indication

• Alcoholic Fatty Liver Disease
• Alcoholic Liver Hepatitis
• Liver Fibrosis
• Liver Cirrhosis

By Treatment

• Pentoxifylline
• Glucocorticosteroids
• Prednisone
• Triamcinolone
• Prednisolone
• Betaine
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Pharmacies
• Others

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape in Alcoholic Liver Diseases Treatment Market:

• Johnson And Johnson Betaine, Inc.
• Sanofi
• Upsher-Smith Laboratories, LLC
• F. Hoffmann-La Roche AG
• Novartis AG
• GlaxoSmithKline plc.
• Pfizer Inc.
• Bayer AG

Recent developments by key players in the Alcoholic Liver Diseases Treatment Market:

GlaxoSmithKline plc.

• In May 2025, GSK agreed to acquire efimosfermin, a drug for liver disease currently in Phase III trials, for up to $2 billion. This deal includes an upfront payment of $1.2 billion, with the possibility of an additional $800 million in milestone payments. The therapy, which is administered via monthly subcutaneous injections, targets steatotic liver disease (SLD) and metabolic-associated steatotic liver disease (MASH), with a planned launch anticipated around 2029.

Novartis AG

• Continues to aggressively expand its pipeline, most notably by acquiring Anthos Therapeutics for up to US $3.1 billion. This acquisition enables the company to regain rights to abelacimab, an investigational factor XI inhibitor designed to prevent blood clots and strokes, with Phase III trials currently underway.
• While focused on cardiovascular goals, this highlights Novartis’s broader strategy of emphasizing late-stage, high-value assets.

Buy now the latest version of this report: https://www.futurewiseresearch.com/checkout.aspx?ReportId=11852&license=multi

**Objectives of this Study: **

1. To provide a comprehensive analysis of the Alcoholic Liver Diseases Treatment Market By Indication, By Treatment, By Distribution Channel and By Region.
2. To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
3. To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
4. To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

                                                                                                                
Flexible Delivery Model:

• We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
• The customization services offered are free of charge with the purchase of any license of the report.
• You can directly share your requirements/changes to the current table of contents to: [email protected]